From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management
Livers · 06.11.2026 · 6 (6) · 116
DOI: 10.3390/livers6060116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 06.11.2026. Verfasst von Ralf Weiskirchen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The publication of the joint EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy represents a watershed moment in hepatology [...]
Zitieren
APA
Weiskirchen, R. (2026). From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management. Livers, 6(6), 116. https://doi.org/10.3390/livers6060116
Vancouver
Weiskirchen R. From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management. Livers. 2026;6(6):116. doi:10.3390/livers6060116
BibTeX
@article{Weiskirchen2026,
author = {Weiskirchen, Ralf},
title = {From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management},
journal = {Livers},
year = {2026},
volume = {6},
number = {6},
pages = {116},
doi = {10.3390/livers6060116}
}
EUVIMED